The new multiple sclerosis vaccine seems to be harmless and quite valuable as it brings about some valuable changes in such patients. The cause of the disease is still unknown but it seems that the immune system attacks the myelin sheaths that protect nerve cells in the brain and spinal cord.
These immune cells and antibodies recognize and attack specific substances in the myelin, such as myelin basic protein .It has also been seen that Certain multiple sclerosis vaccine small proteins produced by cells that trigger inflammation has a significant role in the event. All this damages the nerve cell's axon, which transmits messages to other neurons.
Scientists Identify New Genetic Risk Factors for Multiple Sclerosis
Investigators on Sunday reported the biggest breakthrough in decades into the genetic drivers for multiple sclerosis (MS), identifying two genes that each boost the risk of developing
Advertisement
Amit Bar-Or, M.D., of the Montreal Neurological Institute and colleagues tested a DNA vaccine, BHT-3009, that encodes a full-length human myelin basic protein. Between 2004 and 2006, the researchers administered the vaccine to 30 patients with relapsing-remitting MS [characterized by symptomatic periods and periods of remission] or secondary progressive MS [when symptoms progressively worsen, but there still may be periods of remission].
After one, three, five and nine weeks, participants received intramuscular injections of placebo or BHT-3009 (in doses of .5 milligrams, 1.5 milligrams or 3 milligrams), with or without 80-milligram pills of atorvastatin calcium, a lipid-lowering drug previously shown to be effective in autoimmune conditions. After 13 weeks, participants who initially received placebo received four injections of BHT-3009.
![Tackling Multiple Sclerosis Earlier On Slows Progression]( "Tackling Multiple Sclerosis Earlier On Slows Progression")
According to a study in the Lancet, early use of the drug interferon beta-1b can significantly delay progression of multiple sclerosis (MS).
Magnetic resonance imaging (MRI) and other safety evaluations were performed at the beginning of the study, and again after five, nine, 13, 26, 38 and 50 weeks. "BHT-3009 was safe and well tolerated, provided favorable trends on brain MRI and produced beneficial antigen-specific immune changes," the authors write.
These changes included a reduction in the number of cytokine-producing CD4+ T cells (a type of white blood cell) specifically targeting myelin proteins. This reduction was found in the blood as well as in the cerebrospinal fluid of three patients who voluntarily underwent lumbar puncture after completing the course of BHT-3009.
Atorvastatin did not appear to provide additional benefit."There were no increases in clinical relapses, disability, drug-associated laboratory abnormalities, adverse events or the number and volume of contrast-enhancing [visible on MRI] lesions on brain MRI with BHT-3009 treatment compared with placebo," the authors write. "In fact, there was a trend toward a decrease in the number and volume of contrast-enhancing lesions in the brain in patients treated with BHT-3009 compared with placebo."
Based on these results, a phase 2b trial—a randomized clinical trial in approximately 290 patients—of BHT-3009 is already under way. "If successful in MS, antigen-specific DNA vaccines can be developed for prevention or treatment of related diseases, such as type 1 diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis and myasthenia gravis," the authors conclude.
Source: Eurekalert
BIN/J
Tackling Multiple Sclerosis Earlier On Slows Progression
According to a study in the Lancet, early use of the drug interferon beta-1b can significantly delay progression of multiple sclerosis (MS).
Advertisement
Magnetic resonance imaging (MRI) and other safety evaluations were performed at the beginning of the study, and again after five, nine, 13, 26, 38 and 50 weeks. "BHT-3009 was safe and well tolerated, provided favorable trends on brain MRI and produced beneficial antigen-specific immune changes," the authors write.
These changes included a reduction in the number of cytokine-producing CD4+ T cells (a type of white blood cell) specifically targeting myelin proteins. This reduction was found in the blood as well as in the cerebrospinal fluid of three patients who voluntarily underwent lumbar puncture after completing the course of BHT-3009.
Atorvastatin did not appear to provide additional benefit."There were no increases in clinical relapses, disability, drug-associated laboratory abnormalities, adverse events or the number and volume of contrast-enhancing [visible on MRI] lesions on brain MRI with BHT-3009 treatment compared with placebo," the authors write. "In fact, there was a trend toward a decrease in the number and volume of contrast-enhancing lesions in the brain in patients treated with BHT-3009 compared with placebo."
Based on these results, a phase 2b trial—a randomized clinical trial in approximately 290 patients—of BHT-3009 is already under way. "If successful in MS, antigen-specific DNA vaccines can be developed for prevention or treatment of related diseases, such as type 1 diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis and myasthenia gravis," the authors conclude.
Source: Eurekalert
BIN/J
New Imaging Technique may Help Detect Multiple Sclerosis Early
Purdue University researchers say that new imaging technique, called coherent anti-Stokes Raman cattering microscopy (CARS), can be helpful in early detection of multiple sclerosis.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest General Health News
In a tragic incident, a woman in the US experienced the loss of all her limbs as a result of a bacterial outbreak linked to the consumption of contaminated fish.
FluMos-v2, a unique universal influenza vaccine candidate, undergoing a phase 1 trial at NIH, increases recipients' immunity against many influenza viruses.
In Pakistan, the polio campaign focuses on more than 270,000 children under the age of five years, residing in areas with insufficient vaccine coverage.
Dangers of Wrong Diagnosis: Diagnostic errors in healthcare can increase the risk of permanent disabilities and deaths.
Due to our constant connectivity and the ability to be accessible at all times, it has become challenging to separate from work and fully participate in personal life.
